APA (7th ed.) Citation

Ogawa, E., Tanaka, A., Harada, K., Yatsuhashi, H., Murata, K., Kimura, M., . . . Kimura, K. Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: An investigator-initiated, open-label, non-randomised, two-centre, phase 1 study. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Ogawa, Eiichi, et al. Feasibility, Safety and Tolerability of the CREB-binding Protein/β-catenin Inhibitor OP-724 in Patients with Advanced Primary Biliary Cholangitis: An Investigator-initiated, Open-label, Non-randomised, Two-centre, Phase 1 Study. BMJ Publishing Group.

MLA (9th ed.) Citation

Ogawa, Eiichi, et al. Feasibility, Safety and Tolerability of the CREB-binding Protein/β-catenin Inhibitor OP-724 in Patients with Advanced Primary Biliary Cholangitis: An Investigator-initiated, Open-label, Non-randomised, Two-centre, Phase 1 Study. BMJ Publishing Group.